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To determine (a) whether chronic  heart failure with reduced ejection fraction (HFrEF) is 
associated with increased glycocalyx shedding; (b) whether glycocalyx shedding in HFrEF 
with left ventricular dyssynchrony is related to inflammation, endothelial dysfunction and/or 
redox stress and is ameliorated by cardiac resynchronisation therapy.  
Background: 
Glycocalyx shedding has been reported to be increased in heart failure and is a marker of 
increased mortality. Its role in dyssynchronous systolic heart failure and the effects of cardiac 
resynchronisation therapy (CRT) are largely unknown. 
Methods : 
Twenty-six patients with dyssynchronous HFrEF were evaluated before and 6 months after 
CRT insertion. Echocardiographic septal to posterior wall delay (SPWD) assessed intra-
ventricular mechanical dyssynchrony, and quality of life, integrity of nitric oxide (NO) 
signalling, inflammatory and redox-related biomarkers were measured. Glycocalyx shedding 
was quantitated via plasma levels of the glycocalyx component, syndecan-1. 
Results: 
Syndecan-1 levels pre-CRT were inversely correlated with LVEF (r=-0.45, p=0.02) and 
directly with SPWD (r=0.44, p=0.02), QOL (r=0.39, p=0.04), plasma NT-proBNP (r =0.43, 
p= 0.02), and the inflammatory marker, symmetric dimethylarginine (SDMA) (r=0.54, 
p=0.003). On multivariate analysis, syndecan-1 levels were predicted by SPWD and SDMA 
(β=0.42, p=0.009 and β=0.54, p=0.001, respectively). No significant correlation was found 
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between syndecan-1 levels and other markers of endothelial dysfunction/inflammatory 
activation. Following CRT there was no significant change in syndecan-1 levels. 
Conclusions:  
In patients with dyssynchronous HFrEF, markers of glycocalyx shedding are associated with 
magnitude of mechanical dyssynchrony and elevation of SDMA levels and inversely with 
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List of abbreviations: 
CRT: cardiac resynchronisation therapy 
SPWD: Septal to posterior wall delay. 
QOL : Quality of life  
LVEF: Left ventricular ejection fraction 
NT-proBNP: N-terminal pro brain natriuretic peptide 
AIX : Augmentation index 
NO: nitric oxide 
SDMA: Symmetric dimethylarginine 
TXNIP: thioredoxin interacting protein. 
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Introduction 
In spite of several ground-breaking advances in the understanding and management of heart 
failure over the last few decades, HFrEF remains common in most Western societies with 
substantial associated morbidity, mortality and economic burden [1]. This underscores the 
need for further understanding of the pathophysiological mechanisms of heart failure. It is 
known that chronic heart failure is associated with immune and inflammatory activation [2], 
as well as with vascular endothelial dysfunction [3] with its associated potential for 
disturbance in laminar blood flow [4]. There is increasing evidence that shedding of the 
vascular endothelial glycocalyx may represent a link between these two processes [5], largely 
via activation of matrix metalloproteinases [6] and resultant induction of endothelial 
dysfunction. However, the extent of endothelial glycocalyx shedding in patients with severe 
HFrEF and concomitant left ventricular dyssynchrony, and its putative association with nitric 
oxide signalling and inflammatory activation, remain largely unexplored. Importantly, a direct 
correlation between glycocalyx shedding and loss of laminar blood flow has been observed 
[7]. 
Over the last two decades, cardiac resynchronisation therapy (CRT) has emerged as the 
standard of care in patients with HFrEF associated with concomitant dyssynchronous 
ventricular contractions, especially with left bundle branch block. CRT offers symptomatic 
benefit to approximately two-thirds of recipients; several landmark trials have shown that 
CRT, with or without defibrillator insertion, not only improves ‘soft’ clinical end-points, but 
also reduces risk of mortality and reduces heart failure hospitalisations [8, 9]. The basis for 
this benefit of CRT remains uncertain but it is thought that reduction in dyssynchrony 
contributes to improvement in clinical status [10]. Nonetheless, large multi-centre prospective 
trials have suggested that no echocardiographic measure of dyssynchrony is sufficient by 
itself to predict response to CRT [11]. 
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Recently, efforts to understand the mechanisms of benefit associated with CRT have begun to 
address factors beyond improvement in left ventricular contractile efficiency, turning to 
possible effects on peripheral vascular function [12-14]. It is now known that the integrity of 
the endothelial glycocalyx layer plays a prominent role in maintenance of vascular endothelial 
function by modulating vascular permeability, coagulation, vascular tone, and complement 
activation [15]. Increased glycocalyx shedding occurs in conditions of increased shear and 
oxidative stress [7]. Release into plasma of syndecan-1, a marker of glycocalyx shedding and 
thus of endothelial dysfunction, has been found to be increased in patients with heart failure 
[16]. This elevation of plasma syndecan-1 concentrations is also a correlate of increases in the 
combined end point of all-cause mortality and hospitalised heart failure in patients with heart 
failure with preserved ejection fraction [17]. The role of glycocalyx shedding in patients with 
systolic heart failure and concomitant left ventricular dyssynchrony remains unknown.  
 
 
Objectives of the current study 
1. To confirm activation of glycocalyx shedding in chronic dyssynchronous HFrEF and 
to identify the clinical determinants of the extent of this putative change with 
particular regard to severity of heart failure and extent of left ventricular 
dyssynchrony. 
2. To evaluate the potential interactions of glycocalyx shedding with concomitant 
inflammation, endothelial dysfunction and redox stress, and in particular to determine 
whether glycocalyx shedding is associated with: 
a. Impaired function of the NO signalling cascade 
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b. Increased expression of the inflammatory activator, thioredoxin-interacting 
protein (TXNIP), the expression of which is increased by non-laminar flow 
[18]. 
      3. To determine whether CRT, possibly by ameliorating non-laminar flow, reduces the 
extent of glycocalyx shedding. 
 
Methods 
Patients with conventional indications for CRT (n=26) were prospectively evaluated before 
and six months after CRT implant. Patients’ quality of life was evaluated using the Minnesota 
Living with Heart Failure Questionnaire, with higher scores indicating more impaired quality 
of life.  
 Echocardiographic measurements 
All echocardiographic measurements were performed according to the American Society of 
Echocardiography and European Association of Cardiovascular Imaging guidelines [19]. A 
Phillips echocardiogram machine model iE33, 2009, Bothell WA, 98041 USA was used for 
image acquisition and analyses were performed using Echopac Software Only BT 11 Version 
113, 2013 General Electric Co. M-mode echocardiographic analysis was used to assess left 
ventricular intra-ventricular dyssynchrony. Septal to posterior wall delay (SPWD) was 
calculated as the time difference between the onset of the QRS to the peak of deformation of 
the inter-ventricular septum and the left ventricular posterior wall. Although extent of 
dyssynchrony was analysed as a continuum, SPWD of 130ms or more was considered 
diagnostic of clinically significant intra-ventricular mechanical dyssynchrony [20]. Left 
ventricular volumes including end-diastolic, end-systolic and stroke volumes were measured 
in two dimensions and ejection fraction calculated by the modified Simpson’s method in 
biplane using 2D images. 
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Radial artery applanation tonometry: determination of augmentation index. 
Vascular endothelial function was assessed by changes in augmentation index (AIX) using 
radial artery applanation tonometery as previously described [21]. 
Briefly, patients were first rested in a supine position for 30minutes.  Using a commercially 
available pulse waveform analyser, the SphygmoCor system (AtCor Medical, Sydney, 
Australia, model CvMS V9) baseline AIX was computed as the average of three readings. 
Sublingual nitroglycerin (NTG 300µg) was administered and AIX re-measured every 5 
minutes for twenty minutes. The difference between the lowest value of AIX with NTG and 
the baseline AIX (that is, the maximum change in AIX with NTG) was utilised as a measure of 
endothelium- independent NO signalling. Subsequently, 400µg of inhaled salbutamol was 
administered and measurements were repeated every 5 minutes for twenty minutes. The 
difference between the lowest AIX with salbutamol and the baseline (the maximum change in 
AIX with salbutamol) represents a measure of endothelium-dependent  NO signalling [22]. 
Using the acquired radial artery waveform, a validated, generalized transfer function was used 
to generate the corresponding central aortic pressure waveform from which AIX values were 
calculated.  All measurements were indexed to a heart rate of 75 beats per minute and only 
high fidelity tracings were used. 
 
Platelet expression of thioredoxin-interacting protein.(TXNIP) 
Platelet expression of TXNIP was quantitated by immunofluorescence as previously 
described [23].  
 
Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) 
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For estimation of asymmetric dimethylarginine and symmetric dimethylarginine 
concentrations in plasma, 10ml of blood was collected in heparinised vacutainer tubes and 
immediately put in ice, before centrifugation at 40C at 1800g for 15 minutes. Plasma was 
collected in Eppendorf tubes and stored at -700C until analysed. Subsequent determination 
was performed via high performance liquid chromatography as described by Heresztyn et al 
[24].  
 
Matrix metalloproteinase-2 and matrix metalloproteinase-9 
Matrix metalloproteinase-2 was estimated from blood samples collected in EDTA tubes while 
matrix metalloproteinase-9 was estimated from blood samples collected in heparinised tubes. 
For both, collected blood was immediately put on ice and was centrifuged for 15 minutes at 
1800g at 4oC within 30 minutes of collection. Plasma was collected and stored at -70oC until 
analysed. Assays were performed with RnD Quantikine quantitative sandwich enzyme-linked 
immunosorbent assay (ELISA) kits (Minneapolis USA) according to the manufacturer’s 
instructions. 
 
Platelet aggregometry test; responsiveness to NO 
Platelet response to NO was assessed in vitro by whole blood impedance aggregometry 
according to a previously described protocol [25]. Therapy with P2Y12 receptor antagonists 
was temporarily interrupted prior to carrying out the tests in order not to interfere with ADP 
responses. 
 
N-Terminal proBNP levels 
Samples were collected in heparinised tubes and analysed for NT-proBNP levels with the 
Elecsys proBNP system (Roche diagnostics GmbH, Sandhofer Strasse 116, D-68305 
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Mannheim, Germany). The Sandwich principle was used according to manufacturer’s 
instructions. 
 
Plasma metanephrine and normetanephrine 
Analyses for catecholamine metabolites were performed with fresh samples collected in 
K3EDTA bottles and analysed utilizing liquid chromatography-tandem mass spectrometry. 
The upper limits of the normal range for plasma concentrations were 500 pmol/L for free 
metanephrine and 900 pmol/L for free normetanephrine. 
 
Measurement of plasma levels of syndecan-1.  
For syndecan-1 assay, blood was collected in EDTA tubes and immediately put on ice and 
centrifuged for 15 minutes at 1800g at 4oC within 30 minutes of collection. Plasma was 
collected and stored at -70oC until analysed. Analysis was performed utilizing Human 





The study complied with the Declaration of Helsinki and approval for the study was granted 
by the Ethics and Human Research Committee of The Queen Elizabeth Hospital and all 
participants provided written informed consent. 
 
Statistical analyses 
All data are expressed as mean ± SD unless stated otherwise. Univariate correlations between 
syndecan-1 levels and endothelial/NO- signalling, echocardiographic parameters and 
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neurohumoral activation were performed using Pearson correlation coefficients for normally 
distributed data and Spearman correlation for non-parametric data. Backward stepwise 
multiple regression analysis was performed utilising parameters with significant univariate 
correlations with baseline syndecan-1 levels. The interaction of CRT with glycocalyx 
shedding was assessed by Wilcoxon matched-pairs signed rank test. Apart from the multiple 
regression analyses performed using SPSS 23 version 11.8.2 (2013 Citrix systems), all other 
analyses were performed using Prism 6 for Mac OS X version 6.0h October 2015. 
A p-value < 0.05 was considered statistically significant. 
 
Results 
The baseline characteristics of patients are listed in Table 1. Half of the patients had an 
ischaemic basis for heart failure, the majority had class III-IV symptomatic status and all had 
substantial evidence of dyssynchrony both electrically and mechanically. All patients were 
also extensively treated medically for systolic heart failure prior to CRT implantation. The 
biochemical and physiological data for this group are summarized in Table 2. 
In general, renal function was well preserved, as was platelet response to the NO 
donor, sodium nitroprusside. Median syndecan-1 levels were clearly elevated 
beyond the previously reported range for normal subjects (34.1 ± 8.0 ng/ml [26]. 
 
Univariate correlates of Syndecan-1 at baseline: 
Syndecan-1 levels correlated negatively and significantly with left ventricular ejection 
fraction (r=-0.45, p=0.02). There was also a statistically significant positive correlation 
between syndecan-1 levels and septal to posterior wall delay (r=0.44, p=0.02) and a 
statistically significant positive correlation between syndecan-1 and NT-proBNP (r=0.43, p= 
0.02). There was a trend towards a significant positive correlation with plasma 
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normetanephrine (r=0.37, p=0.09). A direct correlation between syndecan-1 levels and degree 
of impairment of quality of life measured with the Minnesota Living with Heart Failure 
Questionnaire (with higher values indicating greater impairment) was also observed (r=0.39, 
p=0.04). These relationships are depicted in Figure 1. 
 
With regard to vascular endothelial function as assessed with applanation tonometry and NO 
signalling, there was no significant correlation between syndecan-1 levels and baseline 
augmentation index (r=-0.23, p=NS), nor with change in augmentation index in response to 
salbutamol(r=-0.12, p=NS). There was also no significant correlation between levels of 
syndecan-1 and those of asymmetric dimethylarginine (ADMA) (r=0.28, p=0.15), inhibition 
of ADP-induced platelet aggregation with sodium nitroprusside (r=-0.33, p=0.12), nor with 
platelet thioredoxin-interacting protein (TXNIP) levels (r=0.22, p=NS). On the other hand, 
there was a strong and significant positive correlation between syndecan-1 and symmetric 
dimethylarginine (SDMA), (r=0.54, p=0.003).  
 
Multivariate determinants of syndecan-1 at baseline 
Backwards stepwise multiple linear regression analysis was performed utilising parameters 
that exhibited significant univariate correlations with syndecan-1 levels (ejection fraction, 
SPWD, SDMA concentrations and NT-pro BNP concentrations, together with baseline eGFR 
(p=0.10 on univariate analysis). 
The results, summarized in Table 3, revealed that baseline SPWD and SDMA concentrations 
were both directly and significantly related to syndecan-1 levels. Importantly, eGFR was not 
significantly related to syndecan-1 levels. 
 
Effects of CRT  
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There was no significant change in syndecan-1 levels between baseline and 6 months post-
CRT median (IQR) 55 ng/ml (39.2-75.2) vs 59 ng/ml (31.7-79.6) respectively, p=0.45. There 
was also no significant correlation between changes in LVEF post-CRT and those in 
syndecan-1 levels at 6 months, (r=0.31, p=0.13). Similarly, no correlations were found 
between changes in syndecan-1 levels and other measures of vascular biology and NO 
signalling including change in baseline augmentation index (r=-0.16, p=NS), change in AIX 
with salbutamol (r=-0.35, p=NS), platelet ADP-aggregation inhibition with sodium 
nitroprusside (r=-0.01, p=NS), ADMA (r= -0.14, p=NS), SDMA (r=0.13, p=NS), nor platelet 
TXNIP content, (r=0.05, p=NS). In addition, there were no significant correlations between 




In this study, we sought to determine whether glycocalyx shedding, as measured by release of 
syndecan-1 into plasma, plays a major part in the pathophysiology of severe systolic heart 
failure associated with extensive left ventricular dyssynchrony. The bases for these 
evaluations were: (1) endothelial glycocalyx shedding may be triggered by inflammatory 
activation, particularly involving matrix metalloproteinases [27], and (2) in turn may 
precipitate endothelial dysfunction and abnormal responsiveness of blood vessels to shear 
stress: all of which have been reported in systolic heart failure [4]. 
To date, there have been 2 reported clinical studies relevant to the current observations.  
Tromp et al [17] performed an evaluation of syndecan-1 levels in a large cohort of patients 
with chronic heart failure, many of whom had preserved ejection fractions. Levels of 
syndecan-1 were not elevated beyond the normal range (median 20.1ng/ml), and these 
exhibited correlations on multivariable regression analyses with markers of fibrosis and 
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remodelling, but not with extent of LV systolic dysfunction. No correlations with extent of 
dyssynchrony were sought. A Brazilian study [16] of patients with acutely decompensated 
heart failure (with mean LVEF of 41.5 ±14.4%) revealed far greater mean syndecan-1 levels 
(approximately 130ng/ml), which were correlated with extent of acute kidney injury and with 
in-hospital mortality rate. The current study is therefore the first to indicate that chronic 
systolic heart failure is associated with evidence of increased glycocalyx shedding. 
 
In the current study, univariate analyses suggested that the extent of syndecan-1 elevation was 
directly related both to the degree of impairment of LVEF and also to the degree of 
mechanical dyssynchrony. As regards correlations with biochemical/physiological markers, to 
our surprise there was no correlation between syndecan-1 levels any parameters of integrity of 
NO signalling, given that in canine models, the integrity of the endothelial glycocalyx layer 
had been found to flow-mediated NO synthesis[28].  To the best of our knowledge, no 
previous study had evaluated this putative association in human studies. Therefore it appeared 
that variability in NO signalling in such patients may have primarily reflected factors such as 
treatment modalities [29, 30]. In support of this possibility, syndecan-1 levels noted in the 
Brazilian cohort of patients with acutely decompensated heart failure[16] were much higher 
than in the currently evaluated patients. In our centre, we have also observed that in patients 
with acute takotsubo cardiomyopathy, plasma syndecan -1 levels were much higher (97 ± 
65ng/ml) [31] than in our cohort of patients with chronic HFrEF, who were already receiving 
optimal medical treatment.    
Syndecan-1 levels also exhibited direct univariate correlations with NT-proBNP and SDMA 
and this is consistent with greater cardiomyocyte distension and increased  inflammation 
respectively[32, 33].  
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On multivariate analyses, there were persistent significant associations with degree of 
mechanical dyssynchrony and with SDMA levels; the latter remained significant after taking 
eGFR values into account, which is important given the substantial influence of renal function 
on SDMA clearance [34]. On the other hand, TXNIP expression, which might have been 
expected to be a direct correlate, given its association with non-laminar flow [18], exhibited 
no significant association with syndecan-1 levels. Again this may well reflect suppression of 
TXNIP expression by ACE inhibitor therapy [35]. 
 
CRT did not reduce syndecan-1 levels 6 months post procedure in spite of the fact the cohort 
as a whole exhibited significant improvement in LVEF as well as in clinical symptoms. Thus 
the lack of effect on syndecan -1 levels may indicate that CRT is relatively ineffective in 
restoring laminar flow, and/or that the deposition of fibrous tissue leads to ongoing 
inflammatory activation, which perpetuates glycocalyx shedding 
 
As regards the two significant correlates of syndecan-1 levels on multivariate analyses, (that 
is, with dyssynchrony and SDMA levels), only association, rather than causation, can be 
identified definitely at this stage. However, syndecan-1 release appears to engender fibrotic 
change in tissues [17], and indeed conducting system fibrosis is likely to be critical to 
development of mechanical dyssynchrony [36]. As regards SDMA, this is generated by 
protein catabolism and cleared largely, but not entirely, unchanged in the urine. Since it has 
also been suggested that SDMA may represent a surrogate for glomerular function [34], it is 
important that its association with syndecan-1 levels was independent of eGFR. Since it has 
recently emerged that SDMA contributes to inflammatory activation [37], the association 
with syndecan-1 may reflect the inflammatory origin of glycocalyx shedding, but SDMA may 
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The study was limited mainly by its small size, with possible risk of Type 2 error, for 
example, regarding effect of CRT insertion, which might have expected to lower syndecan-1 
levels, and also relationship with extent of systolic dysfunction. Importantly, the patients were 
extensively treated medically and this may have affected findings. Finally, as mentioned 
earlier, we are unable to draw any definite conclusions regarding cause- and- effect 
relationships, but it does appear that reducing mechanical dyssynchrony by CRT does not 
reverse glycocalyx shedding. 
 
Conclusions: 
In this study, we demonstrated for the first time that in patients with severe left ventricular 
systolic dysfunction and concomitant mechanical dyssynchrony, the activation of glycocalyx 
shedding and that the extent of this process correlated directly with the degree of left 
ventricular mechanical dyssynchrony. Furthermore, independent of renal function, glycocalyx 
shedding is also associated with significantly higher plasma levels of the inflammatory 
marker, SDMA. Larger studies and perhaps with patients with less advanced stages of heart 
failure are required to shed more light on the possible effects of CRT in patients with systolic 










Patients under consideration for cardiac resynchronisation therapy (CRT) 
usually constitute a group with severe systolic heart failure refractory to 
conventional pharmacotherapy. In the current study, we provide the first clinical 
evidence that such CRT candidates suffer from acquired damage to the 
glycocalyx, or outer layer of endothelial cells. This will cause increased 
capillary permeability, predisposing towards development of congestion 
irrespective of severity of hemodynamic changes. Interestingly, glycocalyx 
damage increased directly with the extent of mechanical dyssynchrony, but was 
not reversed within 6 months of CRT insertion 
 
Translational outlook: 
Glycocalyx ‘shedding’ is a well-described process activated by pro-
inflammatory enzymes such as matrix metalloproteinases. In animal models, 
inhibition of these enzymes, for example by low dose doxycycline, reverses 
damage to the glycocalyx, and ameliorates circulatory disturbances. The results 
of the current study should therefore increase therapeutic focus on peripheral 
circulatory hemostasis in severe heart failure, and potential for institution of 
treatments to protect the glycocalyx in such patients. 
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Figure 1: Univariate correlates of clinical, echocardiographic and biochemical plasma 
concentrations of syndecan-1 at baseline:  
A: with LVEF 
B: with SPWD  
C: with NT-proBNP  
D: with normetanephrine 
E: with QOL score 
 
Figure 2: NO and redox-signalling correlates of plasma syndecan-1 levels at baseline  
A: Baseline AIx 
B: AIx change with salbutamol 
C: Platelet aggregation inhibition with sodium nitroprusside(SNP)  
D: with TXNIP  
E: with SDMA  
 
